MedTrace Logo

PMS to Evaluate the Safety and Efficacy of Picato® Gel

NCT02421471 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1324

Last updated 2019-12-13

No results posted yet for this study

Summary

This study is a mandatory post launch observational study in South Korea of 3.000 patients receiving treatment for the first time with a new medicinal product, ingenol mebutate gel (Picato®), approved for topical treatment of actinic keratosis.

Each patient is observed for 8 weeks after treatment completion.

Conditions

  • Actinic Keratosis

Interventions

DRUG

Ingenol mebutate 0.015 percent or 0.05 percent gel

Topical treatment with ingenol mebutate gel 0.015 percent or 0.05 percent gel of skin areas affected by AK

Sponsors & Collaborators

  • LEO Pharma

    lead INDUSTRY

Principal Investigators

  • Sun Choi, B.Sc. · LEO Pharma Limited, Korea

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2018-01-19
Completion
2018-01-19

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02421471 on ClinicalTrials.gov